| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 45 | 2025 | 780 | 8.990 |
Why?
|
| United States Department of Veterans Affairs | 29 | 2025 | 555 | 3.220 |
Why?
|
| Maternal Health Services | 9 | 2025 | 68 | 3.010 |
Why?
|
| Depression, Postpartum | 11 | 2024 | 129 | 2.670 |
Why?
|
| Prenatal Care | 8 | 2025 | 174 | 2.560 |
Why?
|
| Pregnancy | 40 | 2025 | 2370 | 2.130 |
Why?
|
| Doulas | 3 | 2025 | 9 | 2.080 |
Why?
|
| Veterans Health | 12 | 2025 | 157 | 1.730 |
Why?
|
| Musculoskeletal Pain | 2 | 2024 | 28 | 1.640 |
Why?
|
| Depression | 12 | 2023 | 909 | 1.520 |
Why?
|
| Military Personnel | 7 | 2024 | 120 | 1.480 |
Why?
|
| Mental Health Services | 5 | 2022 | 290 | 1.350 |
Why?
|
| United States | 35 | 2025 | 7923 | 1.300 |
Why?
|
| Qualitative Research | 7 | 2025 | 728 | 1.220 |
Why?
|
| Pregnancy Complications | 5 | 2024 | 383 | 1.180 |
Why?
|
| Female | 69 | 2025 | 33350 | 1.150 |
Why?
|
| Cesarean Section | 3 | 2024 | 104 | 1.120 |
Why?
|
| Chronic Pain | 2 | 2024 | 156 | 1.120 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2025 | 489 | 1.080 |
Why?
|
| Adult | 45 | 2025 | 17116 | 1.020 |
Why?
|
| Postpartum Period | 6 | 2024 | 196 | 1.000 |
Why?
|
| Health Services Accessibility | 8 | 2025 | 575 | 0.850 |
Why?
|
| Humans | 76 | 2025 | 64238 | 0.850 |
Why?
|
| Personal Autonomy | 1 | 2024 | 71 | 0.820 |
Why?
|
| Stress Disorders, Post-Traumatic | 6 | 2024 | 402 | 0.810 |
Why?
|
| Mothers | 3 | 2024 | 276 | 0.770 |
Why?
|
| Infertility | 1 | 2023 | 31 | 0.760 |
Why?
|
| Evidence-Based Practice | 1 | 2023 | 84 | 0.760 |
Why?
|
| Racism | 1 | 2024 | 88 | 0.750 |
Why?
|
| Peripartum Period | 4 | 2020 | 21 | 0.740 |
Why?
|
| Pain Management | 1 | 2024 | 169 | 0.740 |
Why?
|
| Telemedicine | 2 | 2025 | 344 | 0.690 |
Why?
|
| Mental Health | 7 | 2023 | 372 | 0.680 |
Why?
|
| Anxiety | 3 | 2023 | 430 | 0.670 |
Why?
|
| Perinatal Care | 4 | 2022 | 69 | 0.670 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2019 | 134 | 0.660 |
Why?
|
| Burnout, Professional | 1 | 2022 | 136 | 0.650 |
Why?
|
| Hepatitis, Alcoholic | 4 | 2023 | 78 | 0.640 |
Why?
|
| Smoking Cessation | 2 | 2021 | 551 | 0.570 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 531 | 0.560 |
Why?
|
| Continuity of Patient Care | 2 | 2019 | 174 | 0.560 |
Why?
|
| Sex Offenses | 3 | 2024 | 46 | 0.520 |
Why?
|
| Oxytocics | 1 | 2017 | 14 | 0.510 |
Why?
|
| Pregnancy Outcome | 2 | 2015 | 195 | 0.510 |
Why?
|
| Cohort Studies | 9 | 2024 | 2604 | 0.510 |
Why?
|
| Oxytocin | 1 | 2017 | 45 | 0.500 |
Why?
|
| Premenstrual Syndrome | 2 | 2017 | 99 | 0.490 |
Why?
|
| Infant, Newborn | 7 | 2023 | 1375 | 0.490 |
Why?
|
| Prescription Drugs | 1 | 2015 | 51 | 0.450 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 197 | 0.450 |
Why?
|
| Health Personnel | 3 | 2025 | 389 | 0.440 |
Why?
|
| Middle Aged | 22 | 2025 | 17898 | 0.440 |
Why?
|
| Attitude of Health Personnel | 3 | 2025 | 620 | 0.440 |
Why?
|
| Infant | 6 | 2023 | 1664 | 0.430 |
Why?
|
| Young Adult | 11 | 2020 | 4776 | 0.430 |
Why?
|
| Perception | 2 | 2025 | 178 | 0.420 |
Why?
|
| Pilot Projects | 2 | 2025 | 1019 | 0.360 |
Why?
|
| Interviews as Topic | 2 | 2024 | 539 | 0.360 |
Why?
|
| Adolescent | 11 | 2019 | 6304 | 0.340 |
Why?
|
| Exercise | 1 | 2017 | 954 | 0.310 |
Why?
|
| Psychotherapy, Group | 2 | 2025 | 36 | 0.280 |
Why?
|
| Women's Health | 2 | 2025 | 374 | 0.280 |
Why?
|
| Surveys and Questionnaires | 8 | 2025 | 2737 | 0.280 |
Why?
|
| Prevalence | 4 | 2021 | 1407 | 0.270 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2018 | 77 | 0.260 |
Why?
|
| Male | 20 | 2025 | 30294 | 0.250 |
Why?
|
| Organ Transplantation | 2 | 2020 | 57 | 0.250 |
Why?
|
| Iraq War, 2003-2011 | 5 | 2019 | 66 | 0.250 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 2616 | 0.250 |
Why?
|
| North Carolina | 1 | 2025 | 74 | 0.240 |
Why?
|
| Nephrology | 1 | 2025 | 17 | 0.230 |
Why?
|
| Rural Health Services | 1 | 2025 | 33 | 0.230 |
Why?
|
| Drug Prescriptions | 2 | 2017 | 170 | 0.220 |
Why?
|
| Child | 7 | 2024 | 4583 | 0.220 |
Why?
|
| Afghan Campaign 2001- | 4 | 2019 | 70 | 0.220 |
Why?
|
| Obstetrics | 1 | 2025 | 90 | 0.210 |
Why?
|
| Suicide, Attempted | 1 | 2025 | 107 | 0.210 |
Why?
|
| Sexual Harassment | 2 | 2023 | 15 | 0.210 |
Why?
|
| Interleukin-13 | 1 | 2023 | 37 | 0.210 |
Why?
|
| Women | 1 | 2024 | 44 | 0.200 |
Why?
|
| Health Services Research | 1 | 2025 | 271 | 0.200 |
Why?
|
| Stress, Psychological | 2 | 2019 | 479 | 0.200 |
Why?
|
| Feasibility Studies | 1 | 2025 | 575 | 0.200 |
Why?
|
| Public Policy | 1 | 2023 | 41 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2025 | 147 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2019 | 390 | 0.200 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 61 | 0.200 |
Why?
|
| Abortion, Spontaneous | 1 | 2023 | 31 | 0.200 |
Why?
|
| Age Factors | 3 | 2023 | 1569 | 0.190 |
Why?
|
| Community Health Services | 2 | 2021 | 127 | 0.190 |
Why?
|
| Quality Indicators, Health Care | 1 | 2025 | 335 | 0.190 |
Why?
|
| Pentoxifylline | 1 | 2022 | 8 | 0.190 |
Why?
|
| Abortion, Induced | 1 | 2022 | 27 | 0.180 |
Why?
|
| Antidepressive Agents | 2 | 2022 | 226 | 0.180 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2022 | 11 | 0.180 |
Why?
|
| Mental Disorders | 3 | 2019 | 794 | 0.180 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2022 | 10 | 0.180 |
Why?
|
| End Stage Liver Disease | 1 | 2022 | 34 | 0.180 |
Why?
|
| Job Satisfaction | 1 | 2022 | 141 | 0.180 |
Why?
|
| Breast Feeding | 1 | 2024 | 153 | 0.180 |
Why?
|
| Premature Birth | 1 | 2023 | 115 | 0.180 |
Why?
|
| Soft Tissue Infections | 1 | 2022 | 48 | 0.180 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2021 | 11 | 0.170 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 66 | 0.170 |
Why?
|
| Community-Acquired Infections | 1 | 2022 | 94 | 0.170 |
Why?
|
| Community Networks | 1 | 2021 | 30 | 0.170 |
Why?
|
| Patient Selection | 1 | 2024 | 487 | 0.170 |
Why?
|
| Bacteremia | 1 | 2022 | 94 | 0.170 |
Why?
|
| Vaccines | 1 | 2022 | 98 | 0.170 |
Why?
|
| Staphylococcal Infections | 1 | 2022 | 130 | 0.170 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 26 | 0.170 |
Why?
|
| Pandemics | 2 | 2022 | 676 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 460 | 0.170 |
Why?
|
| Prospective Studies | 7 | 2022 | 3315 | 0.160 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 1272 | 0.160 |
Why?
|
| Decision Making | 1 | 2024 | 416 | 0.160 |
Why?
|
| Hepatitis B virus | 1 | 2020 | 15 | 0.160 |
Why?
|
| Multiple Organ Failure | 1 | 2020 | 45 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2020 | 28 | 0.160 |
Why?
|
| HIV | 1 | 2020 | 70 | 0.160 |
Why?
|
| Counseling | 1 | 2022 | 370 | 0.160 |
Why?
|
| Reproductive Health Services | 1 | 2019 | 13 | 0.160 |
Why?
|
| Health Status | 2 | 2019 | 447 | 0.150 |
Why?
|
| Risk Factors | 9 | 2022 | 5339 | 0.150 |
Why?
|
| Tissue Donors | 1 | 2020 | 154 | 0.150 |
Why?
|
| Health Policy | 1 | 2021 | 195 | 0.150 |
Why?
|
| Smoking | 2 | 2021 | 861 | 0.150 |
Why?
|
| Acute-Phase Proteins | 1 | 2019 | 34 | 0.150 |
Why?
|
| Health Services | 1 | 2019 | 82 | 0.150 |
Why?
|
| Creatine | 1 | 2018 | 24 | 0.150 |
Why?
|
| Sexual Partners | 1 | 2019 | 76 | 0.150 |
Why?
|
| Macrophage Activation | 1 | 2019 | 119 | 0.150 |
Why?
|
| Hepacivirus | 1 | 2020 | 139 | 0.140 |
Why?
|
| Gyrus Cinguli | 1 | 2018 | 57 | 0.140 |
Why?
|
| Connectome | 1 | 2018 | 33 | 0.140 |
Why?
|
| Alcoholism | 1 | 2021 | 323 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2019 | 348 | 0.140 |
Why?
|
| Sperm Count | 1 | 2017 | 15 | 0.130 |
Why?
|
| Recreation | 1 | 2017 | 21 | 0.130 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 267 | 0.130 |
Why?
|
| Semen | 1 | 2017 | 48 | 0.130 |
Why?
|
| Disease Progression | 2 | 2019 | 1176 | 0.130 |
Why?
|
| Cigarette Smoking | 1 | 2017 | 57 | 0.130 |
Why?
|
| Prognosis | 3 | 2019 | 1769 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2019 | 428 | 0.120 |
Why?
|
| Steroids | 1 | 2016 | 55 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 671 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2018 | 317 | 0.120 |
Why?
|
| Medical Record Linkage | 1 | 2015 | 21 | 0.120 |
Why?
|
| Mass Screening | 3 | 2020 | 693 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 457 | 0.120 |
Why?
|
| Length of Stay | 2 | 2020 | 818 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2017 | 872 | 0.120 |
Why?
|
| Quality of Life | 1 | 2022 | 1257 | 0.110 |
Why?
|
| Rehabilitation Centers | 1 | 2015 | 12 | 0.110 |
Why?
|
| Logistic Models | 2 | 2015 | 1270 | 0.110 |
Why?
|
| Infertility, Female | 1 | 2015 | 46 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2017 | 759 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2022 | 1130 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 4 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2022 | 6726 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2019 | 709 | 0.110 |
Why?
|
| Pregnanolone | 3 | 2020 | 15 | 0.110 |
Why?
|
| Tracheostomy | 1 | 2015 | 37 | 0.110 |
Why?
|
| Hydrocortisone | 1 | 2016 | 193 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 848 | 0.110 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 81 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 68 | 0.100 |
Why?
|
| Longevity | 1 | 2015 | 116 | 0.100 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 12 | 0.100 |
Why?
|
| Sertraline | 1 | 2013 | 58 | 0.100 |
Why?
|
| Weight Gain | 1 | 2014 | 168 | 0.100 |
Why?
|
| Fetus | 1 | 2013 | 100 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 39 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2019 | 711 | 0.100 |
Why?
|
| Benzodiazepines | 1 | 2013 | 102 | 0.100 |
Why?
|
| Aged | 10 | 2025 | 14648 | 0.100 |
Why?
|
| Lymphoma | 1 | 2013 | 103 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2017 | 5691 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 25 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2013 | 58 | 0.100 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 52 | 0.100 |
Why?
|
| Colonoscopy | 1 | 2013 | 95 | 0.090 |
Why?
|
| Perimenopause | 1 | 2012 | 31 | 0.090 |
Why?
|
| Weight Loss | 1 | 2014 | 273 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 251 | 0.090 |
Why?
|
| Body Weight | 1 | 2013 | 379 | 0.090 |
Why?
|
| Parturition | 2 | 2023 | 56 | 0.090 |
Why?
|
| Sleep | 1 | 2014 | 231 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2022 | 1561 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2015 | 455 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 199 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 283 | 0.080 |
Why?
|
| Postmenopause | 1 | 2012 | 238 | 0.080 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2012 | 192 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 276 | 0.080 |
Why?
|
| Bipolar Disorder | 1 | 2012 | 247 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 321 | 0.080 |
Why?
|
| Neoplasms | 1 | 2019 | 1392 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2014 | 249 | 0.070 |
Why?
|
| 20-alpha-Dihydroprogesterone | 2 | 2020 | 7 | 0.070 |
Why?
|
| Desoxycorticosterone | 2 | 2020 | 7 | 0.070 |
Why?
|
| Quality of Health Care | 2 | 2025 | 526 | 0.070 |
Why?
|
| Progesterone | 2 | 2020 | 163 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 5520 | 0.060 |
Why?
|
| Aging | 1 | 2012 | 754 | 0.060 |
Why?
|
| Biomarkers | 2 | 2023 | 1431 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 423 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 930 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 151 | 0.050 |
Why?
|
| Depressive Disorder | 2 | 2020 | 286 | 0.050 |
Why?
|
| Lipocalin-2 | 1 | 2023 | 9 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2023 | 15 | 0.050 |
Why?
|
| Rape | 1 | 2023 | 15 | 0.050 |
Why?
|
| Program Development | 1 | 2025 | 207 | 0.050 |
Why?
|
| Gender Identity | 1 | 2024 | 69 | 0.050 |
Why?
|
| Focus Groups | 1 | 2025 | 310 | 0.050 |
Why?
|
| Rural Population | 1 | 2025 | 212 | 0.050 |
Why?
|
| Stillbirth | 1 | 2023 | 17 | 0.050 |
Why?
|
| Birth Weight | 1 | 2023 | 85 | 0.050 |
Why?
|
| Employment | 1 | 2024 | 128 | 0.050 |
Why?
|
| Fertilization | 1 | 2023 | 82 | 0.050 |
Why?
|
| Fertilization in Vitro | 1 | 2023 | 85 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2022 | 38 | 0.050 |
Why?
|
| Leukocidins | 1 | 2022 | 8 | 0.050 |
Why?
|
| Exotoxins | 1 | 2022 | 9 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 30 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 324 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 529 | 0.050 |
Why?
|
| Lactation | 1 | 2022 | 70 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2022 | 66 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 66 | 0.050 |
Why?
|
| Public Health | 1 | 2023 | 186 | 0.040 |
Why?
|
| Bacterial Toxins | 1 | 2022 | 63 | 0.040 |
Why?
|
| Norepinephrine | 1 | 2022 | 103 | 0.040 |
Why?
|
| Zinc | 1 | 2022 | 93 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 979 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 788 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2025 | 437 | 0.040 |
Why?
|
| Object Attachment | 1 | 2020 | 19 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 179 | 0.040 |
Why?
|
| Pregnenolone | 1 | 2020 | 4 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 181 | 0.040 |
Why?
|
| Mother-Child Relations | 1 | 2020 | 47 | 0.040 |
Why?
|
| Tobacco Smoking | 1 | 2020 | 20 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 11 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2021 | 289 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 129 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 37 | 0.040 |
Why?
|
| Hepatitis B | 1 | 2020 | 33 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2021 | 203 | 0.040 |
Why?
|
| New Jersey | 1 | 2019 | 26 | 0.040 |
Why?
|
| Texas | 1 | 2019 | 57 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 371 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 147 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 54 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2019 | 40 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 138 | 0.040 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2018 | 12 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2019 | 91 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 288 | 0.040 |
Why?
|
| Suicidal Ideation | 1 | 2019 | 120 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 222 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2020 | 152 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 458 | 0.030 |
Why?
|
| Social Support | 1 | 2020 | 376 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 587 | 0.030 |
Why?
|
| Parents | 1 | 2021 | 395 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2018 | 203 | 0.030 |
Why?
|
| Marital Status | 1 | 2017 | 45 | 0.030 |
Why?
|
| Semen Analysis | 1 | 2017 | 20 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 735 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 313 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 756 | 0.030 |
Why?
|
| Receptors, GABA-A | 1 | 2016 | 25 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 407 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1102 | 0.030 |
Why?
|
| Saliva | 1 | 2016 | 100 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 438 | 0.030 |
Why?
|
| Vincristine | 1 | 2014 | 28 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 87 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 85 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 407 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 101 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2015 | 127 | 0.030 |
Why?
|
| Hallucinations | 1 | 2013 | 16 | 0.030 |
Why?
|
| Metabolism | 1 | 2013 | 13 | 0.030 |
Why?
|
| Massachusetts | 1 | 2019 | 2094 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 120 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2013 | 17 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 26 | 0.020 |
Why?
|
| Family | 1 | 2015 | 243 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 25 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2012 | 33 | 0.020 |
Why?
|
| HIV Infections | 1 | 2020 | 976 | 0.020 |
Why?
|
| Cytarabine | 1 | 2012 | 38 | 0.020 |
Why?
|
| Overweight | 1 | 2014 | 252 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1669 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 200 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 467 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2046 | 0.020 |
Why?
|
| Premenopause | 1 | 2012 | 61 | 0.020 |
Why?
|
| Global Health | 1 | 2013 | 183 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2012 | 81 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2013 | 206 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 374 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 744 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2015 | 414 | 0.020 |
Why?
|
| Affect | 1 | 2012 | 127 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2015 | 507 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 788 | 0.020 |
Why?
|
| Critical Care | 1 | 2015 | 402 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 859 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2013 | 304 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 1162 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 356 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1383 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 2217 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 2478 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 1368 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2013 | 1294 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 2629 | 0.010 |
Why?
|